Pregnancy Outcomes in the Era of Universal Antiretroviral Treatment in Sub-Saharan Africa (POISE Study).
Adult
Anti-Retroviral Agents
/ therapeutic use
Drug Administration Schedule
Female
HIV Infections
/ drug therapy
Humans
Infant, Newborn
Infectious Disease Transmission, Vertical
/ prevention & control
Malawi
/ epidemiology
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
Pregnancy Outcome
Prospective Studies
Socioeconomic Factors
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
pubmed:
3
10
2018
medline:
7
11
2019
entrez:
2
10
2018
Statut:
ppublish
Résumé
Adverse pregnancy outcomes such as preterm birth (PTB), low birth weight (LBW), and small for gestational age (SGA) remain major global problems. We compared pregnancy outcomes among HIV-infected women receiving antiretroviral treatment (ART) and with CD4 ≥350 cells, and HIV-uninfected women to assess whether disparities associated with HIV infection have been eliminated through use of ART. Observational study conducted at 5 health facilities in Blantyre, Malawi, during 2016-2017. HIV-infected women receiving the national ART regimen (efavirenz + lamivudine + tenofovir) and HIV-uninfected women were consented and enrolled at delivery. Data collected included sociodemographic and clinical; gestational age; BW; infant/maternal anthropometry; and laboratory results. We defined PTB as GA <37 weeks; LBW as BW <2·5 kg; and SGA as BW <10th percentile of GA. SGA infants were classified into proportionate and disproportionate based on ponderal index. Descriptive, stratified, and multivariate logistic and linear regression analyses were used. Of 5423 women approached, 614 HIV-infected and 685 HIV-uninfected women were enrolled. Rates of PTB, LBW, and SGA were 10.6%, 7.2%, and 17.1% among HIV-infected women on ART and 9.5%, 5.0%, and 18.4% among HIV-uninfected women, respectively. None of these differences were statistically significant in univariate- or multivariate-adjusted analyses (P > 0.05). Of 231 SGA infants, 78.8% were proportionate and 21% were disproportionate. Of the 614 HIV-infected women on ART, 75% had undetectable virus at delivery. ART use has reduced the high rates of adverse pregnancy outcomes among HIV-infected women. However, the rates remain high irrespective of HIV infection and require appropriate interventions.
Sections du résumé
BACKGROUND
Adverse pregnancy outcomes such as preterm birth (PTB), low birth weight (LBW), and small for gestational age (SGA) remain major global problems. We compared pregnancy outcomes among HIV-infected women receiving antiretroviral treatment (ART) and with CD4 ≥350 cells, and HIV-uninfected women to assess whether disparities associated with HIV infection have been eliminated through use of ART.
SETTING
Observational study conducted at 5 health facilities in Blantyre, Malawi, during 2016-2017.
METHODS
HIV-infected women receiving the national ART regimen (efavirenz + lamivudine + tenofovir) and HIV-uninfected women were consented and enrolled at delivery. Data collected included sociodemographic and clinical; gestational age; BW; infant/maternal anthropometry; and laboratory results. We defined PTB as GA <37 weeks; LBW as BW <2·5 kg; and SGA as BW <10th percentile of GA. SGA infants were classified into proportionate and disproportionate based on ponderal index. Descriptive, stratified, and multivariate logistic and linear regression analyses were used.
RESULTS
Of 5423 women approached, 614 HIV-infected and 685 HIV-uninfected women were enrolled. Rates of PTB, LBW, and SGA were 10.6%, 7.2%, and 17.1% among HIV-infected women on ART and 9.5%, 5.0%, and 18.4% among HIV-uninfected women, respectively. None of these differences were statistically significant in univariate- or multivariate-adjusted analyses (P > 0.05). Of 231 SGA infants, 78.8% were proportionate and 21% were disproportionate. Of the 614 HIV-infected women on ART, 75% had undetectable virus at delivery.
CONCLUSIONS
ART use has reduced the high rates of adverse pregnancy outcomes among HIV-infected women. However, the rates remain high irrespective of HIV infection and require appropriate interventions.
Identifiants
pubmed: 30272628
doi: 10.1097/QAI.0000000000001875
pmc: PMC6289692
mid: NIHMS1507090
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-14Subventions
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NICHD NIH HHS
ID : R21 HD085874
Pays : United States
Références
JAMA Pediatr. 2017 Oct 2;171(10):e172222
pubmed: 28783807
J Pediatr. 1979 Nov;95(5 Pt 1):769-74
pubmed: 490248
J Infect Dis. 2012 Dec 1;206(11):1695-705
pubmed: 23066160
AIDS. 2007 Mar 12;21(5):607-15
pubmed: 17314523
Lancet. 2013 Aug 3;382(9890):417-425
pubmed: 23746775
Int J Epidemiol. 1995 Oct;24(5):1022-9
pubmed: 8557435
Obesity (Silver Spring). 2014 May;22(5):E149-56
pubmed: 24039223
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):226-34
pubmed: 22692091
J Infect Dis. 2006 May 1;193(9):1195-201
pubmed: 16586354
N Engl J Med. 2016 Nov 3;375(18):1726-1737
pubmed: 27806243
Lancet. 2008 Jan 5;371(9606):75-84
pubmed: 18177778
J Infect Dis. 2015 Jan 1;211(1):10-8
pubmed: 25030058
New Microbiol. 2015 Apr;38(2):185-92
pubmed: 25938743
BMC Pediatr. 2003 Jul 8;3:6
pubmed: 12848901
J Infect Dis. 2016 Apr 1;213(7):1051-4
pubmed: 26265779
Ann Epidemiol. 2018 Dec;28(12):893-900
pubmed: 30293920
AIDS. 2015 Jan 14;29(2):183-91
pubmed: 25426808
J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):383-392
pubmed: 29239901
Early Hum Dev. 1990 Dec;24(3):219-30
pubmed: 2096073
J Infect Dis. 2016 Apr 1;213(7):1057-64
pubmed: 26265780
Lancet Glob Health. 2013 Jul;1(1):e26-36
pubmed: 25103583
J Nutr. 2003 May;133(5 Suppl 2):1592S-1596S
pubmed: 12730473
J Infect Dis. 2015 Jan 1;211(1):4-7
pubmed: 25030057
J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):504-8
pubmed: 16652060
BMJ. 2017 Aug 17;358:j3677
pubmed: 28819030
J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):428-36
pubmed: 26379069
PLoS One. 2012;7(2):e31580
pubmed: 22384039
J Infect Dis. 2007 Mar 15;195(6):914-6; author reply 916-7
pubmed: 17299724